US3905982A - 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds - Google Patents

1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds Download PDF

Info

Publication number
US3905982A
US3905982A US381505A US38150573A US3905982A US 3905982 A US3905982 A US 3905982A US 381505 A US381505 A US 381505A US 38150573 A US38150573 A US 38150573A US 3905982 A US3905982 A US 3905982A
Authority
US
United States
Prior art keywords
dihydro
phenyl
parts
isoquinolinecarboxamide
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US381505A
Other languages
English (en)
Inventor
Peter K Yonan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to US381505A priority Critical patent/US3905982A/en
Priority to GB3217874A priority patent/GB1452398A/en
Priority to ZA00744665A priority patent/ZA744665B/xx
Priority to BE146789A priority patent/BE817917A/xx
Priority to NO742679A priority patent/NO141160C/no
Priority to DE2435168A priority patent/DE2435168A1/de
Priority to IE1546/74A priority patent/IE39630B1/xx
Priority to ES428503A priority patent/ES428503A1/es
Priority to CA205,331A priority patent/CA1041501A/en
Priority to FR7425375A priority patent/FR2238488B1/fr
Priority to JP49084056A priority patent/JPS5041873A/ja
Priority to AT602874A priority patent/AT329563B/de
Priority to DK395174AA priority patent/DK138644B/da
Priority to SE7409496A priority patent/SE387341B/xx
Priority to NL7409881A priority patent/NL7409881A/xx
Priority to AR254830A priority patent/AR202416A1/es
Priority to AU71470/74A priority patent/AU492516B2/en
Priority to CH1014974A priority patent/CH605773A5/xx
Priority to CH1394177A priority patent/CH605774A5/xx
Priority to AR258939A priority patent/AR205380A1/es
Priority to US05/571,638 priority patent/US4001244A/en
Application granted granted Critical
Publication of US3905982A publication Critical patent/US3905982A/en
Priority to ES448973A priority patent/ES448973A1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/52—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring

Definitions

  • the present invention relates to a group of 5 3 ,4-dihydro-2( l H )-isoquinolinecarboxamides. More particularly. the present invention relates to a group of compounds having the oeneral formula X ll -c-lf-Alk-IR'R" I R an I) wherein X and X are each selected from the group consisting of hydrogen, lower alkoxy, hydroxy.
  • lower aikylene groups referred to above contain 2 to 6 carbon atoms and can be exemplified by groups such as ethylene. propylene. trimethylene and 1,4-
  • the halogen atoms include fluorine, chlorine. bromine and iodine.
  • the cycloalkyl groups contain to 7 carbon atoms and include cyclopentyl, cyclohexyl and cycloheptyl.
  • acid addition salts can be derived from a variety of organic and inorganic acids such as sulfuric, phosphoric, hydrochloric. hydrobromic, hydriodic. sulefamic. citric. lactic. maleic. malic. succinic, tartaric. cinnarnic. acetic. benzoic. gluconic. ascorbic and re- .lated acids.
  • the quaternary ammonium salts can be derived from a variety of organic esters of sulfuric, hydrohalic and aromatic sulfonic acids.
  • esters are methyl chloride and bromide, ethyl chloride. propyl chloride. butyl chloride, isobutyl chloride. benzyl chloride and bromide. phenethyl bromide. naphthylmethyl chloride, di-methyl sulfate, methyl benzenesulfonate. ethyl toluene-sulfonate, ethylene chlorohydrin. propylene chlorohydrin. allyl bromide.
  • the compounds of this invention are useful because of their pharmacological properties. in particular, they possess activity as anti-arrhythmic agents. Thus. they bring about a return to normal heat rhythm in animals in which the heart rhythm has become irregular.
  • the anti-arrhythmic utility of the instant compounds is evident from the results of a standardized test for their capacity to slow the ventricular tachycardia induced by aconitine in the isolated rabbit heart.
  • the procedure is essentially that described by Lucchesi [1. Pharrnacol. Exp. Therap.. 137. 291 0962)], modified in certain. particulars as follows: Hearts are obtained from adult albino rabbits of either sex and perfused in apparatus modeled after that devised by Anderson and Craver [.l. Pharrnacol. Exp. Therap.. 93.135 (i948 )1.
  • the composition of the perfusion solution is the same as Lucchesi's, but the volume is increased to 200 ml.
  • Aconitine (ordinarily as the nitrate) is administered as soon as the heart beat is regular and the EKG pattern normal, the dose being so selected as to at least double the rate.
  • 0.05 ml. of 0.l% aconitine nitrate in physiological saline is injected. EKG's are recorded at 5 minute intervals after onset of ventricular tachycardia until two successive readings show stabilization of the rate. Perfusate collected during this time is discarded and replaced with fresh solution q.s. 200 ml. Promptly following stabilization. 2 mg. of compound dissolved or suspended in l ml. of physiological saline is mixed with the perfusion solution.
  • these compounds possess anthelmintic activity. By virtue of their anti-biotic activity.
  • these compounds can be combined with various known excipients and adjuvants in the form of dusts, solutions, suspensions, ointments and sprays to provide compositions useful for disinfecting purposes.
  • the compounds of the present invention can be conveniently prepared by contacting a compound of the formula wherein X, X, Y, Y', n, R, All: and NR'R" are defined as before. Depending on the nature of the reactants, it is possible to carry-out this reaction inthe presence or absence of, a solvent. The use of a solvent is, however,
  • aromatic hydrocarbons such as benzene and tolu- 35 ene
  • ltetones such as acetone and 2-butanone
  • ethers such as ethyl ether, tetrahydrofuran and dioxane.
  • Time and temperature are not critical factors for the conduct of this reaction, typical temperatures varying from room temperature to reflux and typical times being in sewage of 30 minutes to several days.
  • An alternate route to the subject compounds involves contacting a compound of the formula with an appropriate secondary amine of the formula H- -NR'R" 6 wherein X, X, Y, Y, n, All: and NR'R" are defined as before.
  • This reaction is conducted in a suitable'solvent, preferably a ketone (c.g., Z-butanone or ace-' tone).
  • suitable'solvent preferably a ketone (c.g., Z-butanone or ace-' tone).
  • Other possible solvents include aromatic hydro carbons (e.g., benzene and toluene), high boiling cthers (e.g., dioxane), lower allkanols (e.g., methanol and ethanol), dimethylformamide and dimethylsulfoxide.
  • Time and temperature are not critical.-Reaction temperature can vary from room temperature to approximately l00C., with a temperature range of room temperature to 6070C. being typical. Time
  • An alternative process for the preparation of the subject compounds wherein R is a lower allsyl group proceeds by contacting a compound of formula I) wherein R is hydrogen with a lower alltyl halide in the presence of sodium hydride or sodamide.
  • Other possible solvents include ethcrs such as tetrahydrofuran and dioxane.
  • sodamide it; is also possible to employ an aromatic solvent, e.g., benzene or toluene.
  • Time and temperature are not critical.
  • the reaction can be conducted at a temperature ranging from room temperature to lO0C., with a temperature range of room temperature 60-70C. being preferred. Reaction time usually varies from 3 to 24' hours.
  • the compounds of formula (l) wherein X and/or X are/is hydroxy can be prepared from the corresponding compounds of formula (I) wherein X and/or X are/is benzyloxy.
  • Debenzylation is conveniently effected by catalytic hydrogenolysis. Suitable catalysts include platinum, Raney nickel, copper-chromium oxide and palladium (optionally on a support), a particularly preferred catalyst being palladium-on-carbon.
  • the hydrogenation is conveniently conducted in a solvent, the choice of solvent depending upon the particular starting material employed.
  • solvents such as lower alkanols (e.g., methanol, ethanol and 2-propanol), ethers (e.g., tetrahydrofuran), water and acetic acid, could be used.
  • the reaction is generally conducted at a temperature ranging from room temperature to 100C, with a temperature range of room temperature to 50-60C. being typical.
  • novel starting materials of formula (ll) above can be readily prepared by contacting a compound of the formula wherein X, X', Y, Y and n are: as hereinbefore defined with phosgene.
  • EXAMPLE 3 A solution of 45 parts of benzoyl chloride in 149 parts of chloroform is added portionwise over a 30 minute period to a solution of 78 parts of .3-benzyloxy- 4-methoxyphenethylamine in 72 parts of triethylamine and 596 parts of chloroform. The mixture is stirred at room temperature for an additional minutes. it is then washed twice with water and once with dilute aqueous sodium bicarbonate solution. dried over anhydrous calcium sulfate and stripped to a low volume under reduced pressure. Addition of n-hexane results in crystallization of N-(Zi-benzyloxy- 4-methoxyphenethyl)bcnzamide. That product melts at about l36-l38C.
  • EXAMPLE 4 A solution of64 parts of N-(3-benzyloxy-4- methoxyphenethyl)benzamide and 192 parts of phosphorus oxychloride in 348 parts of toluene is refluxed for 3 and hours. The solution is stripped in vacuo -until a precipitate forms. Ethyl ether is added and the mixture is filtered. The solid residue. which is 6- benzyloxy- 7-methoxyl -phenyl-3 ,4-dihydroisoquinoline hydrochloride, is dissolved in water. Dilute aqueous sodium hydroxide solution is added and the mixture is extracted with methylene chloride.
  • EXAMPLE 5 tered.
  • the solid thus obtain is 6,7-dimethoxy-l-phenyl-
  • a suspension of 38 parts of 6-bcnzyloxy-7-methoxyy -Z(lF )osoqutn ztlmecarbonyl ChlOlldc, l-phenyl-3,4-dihydroisoquinoline in 435 parts of etha- P nol is heated to approximately 55C.
  • 32 Parts of sodium subst'muon of cquwalcm of thc borohydride is added portionwise over a minute pertctrahydmisoquinofines indicated bdow for iod, while maintaining the reaction temperature at F ll -C.
  • EXAMPLE 2i 2.0 Parts of '6-benzyloxy-N- (Z-diisopropylaminoethyi) 7-methoxy- I -phenyl-3.4-dihydro-2( lH isoquinolinecarboxamide is dissolved in approximately 80 parts of,methanol. 0.2 Part of a 5% palladium-on-v carbon catalyst is'addeda nd the mixture is shaken at room temperature and a pressure of about2 psi for approximately 23hours or until one molecular equivalent of hydrogenhas been absorbed. The catalyst is removed by filtration and the filtrate is concentrated under reduced pressure to give 'an'oil which solidifies upon trituration with n-pentane.
  • EXAMPLE 22 2.0 Parts of N-(Z-diisopropylaminoethyl)-l-phenyl- 3.4-dihydro'2(lH)-isoquinolinecarboxamide is dissolved in 22.8 parts of methyl iodide and placed in a steam oven at 65C. for about l6 hours. The reaction mixture is then concentrated under reduced pressure and the residue is dissolved in ethanol. Ethyl ether is added and the mixture isrefrigerated until crystallizaoccurs. The product. which is N-(2- diisopropylaminoethyl)-l-phenyl-3,4-dihydro- 2( l H)-isoquinolinecarboxamide 'methiodide. is separated and recrystallized from a mixture of ethanol and ethyl ether.
  • Alk is lower alkylene of 2 to 6 carbon atoms separating the nitrogen atoms attached thereto by at least 2 carbon atoms; and NRR" is selected from the group consisting of di(lower alkyl) amino, N-cyclohexylflower alkylamino), l pyrrolidinyl.hexamethyleneimino. piperidino, 4-phenylpip'eridino, and .4-benzylpiperidino 2.
  • a compound according to claim 1 which has the formula 7.
  • a compound according to claim 1 which is N-(2- diethylaminoethyl)-6.7-dimethoxy-l-phcnyl-3.4- dihydro-2( l H )-isoquinolinecarboxamide.
  • a compound according to claim I which is N-(Z- x II lower alkyl 5 diisopropylaminoethyl)-6 ,7-dimethoxy-l-phenyl-Zl.4- xl lI-C-I-Alk-I dihydro-2( lH)-is0quinolinecarboxamide.
  • a compound according to claim I which has the formula K) x I x -Cm-.CK CH 'N yr wherein X and X are each selected from the group consisting of hydrogen, lower alltoxy. hydroxy. benzyloxy and .methyl, or X and X' together represent a single methylenedioxy or ethylenedioxy group; Y and Y' are each selected from the group consisting of hydrogen, halogen and lower alkoxy; n is selected from the group consisting of 0 and l; R is selected from the group consisting of hydrogen and lower alkyl; and All:
  • Alk is lower alkylene separating the nitrogen atoms attached thereto by at least 2 carbon atoms.
  • X and X' are each selected from the group consisting of lower alkoxy. hydroxy and benzyloxy, or X and X together represent a single methylenedioxy or ethylenedioxy group; and Y and Y' are each selected from the group consisting of hydrogen. halogen and lower alkoxy.
  • a compound according to claim 1 which is N- ⁇ Z- [N-cyclohexyl(methylamino)]cthyl ⁇ -6,7-dimethoxy-l- (4-methoxyphenyl)-3 .4-dihydro-2-(1H)- isoquinolinecarboxamide.
  • a compound according to claim 1 which is N- ⁇ 2- IN-cyclohexyl)methylamino) lethyl ⁇ -6,7-dimethoxyl phenyl-3,4-dihydro-2( 1H )-isoquinolinecarboxamide.
  • a compound according to claim 1 which is 7- eniyloxy-N- ⁇ 2-l N-cyclohexyl( methylamino) lethyl ⁇ loior alkyl -methoxyl -phenyl-3.4-dihydro-2( 1H)- isoquinolinecarbo'xamide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US381505A 1973-07-23 1973-07-23 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds Expired - Lifetime US3905982A (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
US381505A US3905982A (en) 1973-07-23 1973-07-23 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds
GB3217874A GB1452398A (en) 1973-07-23 1974-07-19 1-aryl-n-dialkylaminoalky.-3,4-dihydro-2-1h-isoquinoline carboxamides and related compounds
SE7409496A SE387341B (sv) 1973-07-23 1974-07-22 Forfarande for framstellning av 1-aryl-n-dialkyl-aminoalkyl-3,4-dihydro2(h)-isokinolinkarboxamider
NO742679A NO141160C (no) 1973-07-23 1974-07-22 Analogifremgangsmaate til fremstilling av terapeutisk virksomme 3,4-dihydro-2(1h)-isokinolinkarboksamider
DE2435168A DE2435168A1 (de) 1973-07-23 1974-07-22 1-aryl-n-dialkylaminoalkyl-3,4dihydro-2(1h)-isochinolincarboxamide und verwandte verbindungen
IE1546/74A IE39630B1 (en) 1973-07-23 1974-07-22 1-aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1h)-isoquinolinecarboxamides and related compounds
ES428503A ES428503A1 (es) 1973-07-23 1974-07-22 Procedimiento para preparar compuestos de 3, 4-dihidro-2 (1h)-isoquinolincarboxamida.
CA205,331A CA1041501A (en) 1973-07-23 1974-07-22 1-aryl-n-dialkylaminoalkyl-3,4-dihydro-2 (1h)-isoquinolinecarboxamides and related compounds
FR7425375A FR2238488B1 (no) 1973-07-23 1974-07-22
JP49084056A JPS5041873A (no) 1973-07-23 1974-07-22
ZA00744665A ZA744665B (en) 1973-07-23 1974-07-22 1-aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1h) - isoquinolinecarboxamides and related compounds
DK395174AA DK138644B (da) 1973-07-23 1974-07-22 Analogifremgangsmåde til fremstilling af 1-aryl-N-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolincarboxamider eller deres farmaceutisk acceptable syreadditionssalte eller kvaternære ammoniumsalte.
BE146789A BE817917A (fr) 1973-07-23 1974-07-22 Amides derives de l'isoquinoleine
NL7409881A NL7409881A (nl) 1973-07-23 1974-07-22 Werkwijze ter bereiding van preparaten met an- ti-aritmische activiteit en aldus verkregen pre- paraten, die 1-aryl-n-dialkyl-aminoalkyl-3,4-di- hydro-2(1h)-isochinoline-carboxamiden en verwan- te verbindingen als actieve component bevatten.
AR254830A AR202416A1 (es) 1973-07-23 1974-07-22 Procedimiento para la preparacion de derivados de 1-aril-n-dialquilaminoalquil 3, 4-dihidro-2 (1h)-isoquinolincarboxamidas
AU71470/74A AU492516B2 (en) 1974-07-22 1-aryl-n-dialkylaminoalkyl-3,4-dihydro-2-(1h)-isoquinoline-carboxamides and related compounds
AT602874A AT329563B (de) 1973-07-23 1974-07-22 Verfahren zur herstellung von neuen 3,4-dihydro-2(1h)-isochinolin-carboxamidderivaten und deren salzen
CH1014974A CH605773A5 (no) 1973-07-23 1974-07-23
CH1394177A CH605774A5 (no) 1973-07-23 1974-07-23
AR258939A AR205380A1 (es) 1973-07-23 1975-01-01 Un procedimiento para la preparacion de derivados de 1-aril-n-dialquilaminoalquil 3,4-dihidro-2 (1h)-isoquinolin-carboxamidas
US05/571,638 US4001244A (en) 1973-07-23 1975-04-25 1-aryl-3,4-dihydro-2(1h)-isoquinoline carbonyl chlorides
ES448973A ES448973A1 (es) 1973-07-23 1976-06-16 Procedimiento para preparar compuestos de 3,4-dihidro-2 (ih)-isoquinolincarboxamida.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US381505A US3905982A (en) 1973-07-23 1973-07-23 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US05/571,638 Continuation-In-Part US4001244A (en) 1973-07-23 1975-04-25 1-aryl-3,4-dihydro-2(1h)-isoquinoline carbonyl chlorides

Publications (1)

Publication Number Publication Date
US3905982A true US3905982A (en) 1975-09-16

Family

ID=23505299

Family Applications (1)

Application Number Title Priority Date Filing Date
US381505A Expired - Lifetime US3905982A (en) 1973-07-23 1973-07-23 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds

Country Status (17)

Country Link
US (1) US3905982A (no)
JP (1) JPS5041873A (no)
AR (2) AR202416A1 (no)
AT (1) AT329563B (no)
BE (1) BE817917A (no)
CA (1) CA1041501A (no)
CH (2) CH605774A5 (no)
DE (1) DE2435168A1 (no)
DK (1) DK138644B (no)
ES (2) ES428503A1 (no)
FR (1) FR2238488B1 (no)
GB (1) GB1452398A (no)
IE (1) IE39630B1 (no)
NL (1) NL7409881A (no)
NO (1) NO141160C (no)
SE (1) SE387341B (no)
ZA (1) ZA744665B (no)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678853A (en) * 1986-01-15 1987-07-07 T P O "Pharmachim" 1-(3,4-dimethylbenzyl)-2-(N-alkyl)-carbamoyl tetrahydroiso quinolines
US4767862A (en) * 1985-07-23 1988-08-30 Smithkline Beckman Corporation Substituted tetrahydro isoquinoline intermediates
WO1998057952A1 (en) * 1997-06-19 1998-12-23 Sepracor Inc. Isoquinoline-indole compounds as antimicrobial agents
RU2141478C1 (ru) * 1995-06-07 1999-11-20 Пфайзер Инк. Амиды, фармацевтическая композиция, способы снижения секреции аполипопротеина в, соединение
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6172084B1 (en) 1997-06-19 2001-01-09 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US20040149658A1 (en) * 2001-08-03 2004-08-05 Dukhin Andrei S. Method for the removal of heavy metals from aqueous solution by means of silica as an adsorbent in counter-flow selective dialysis
US20060229524A1 (en) * 2005-04-08 2006-10-12 Alden Ozment Method for the accurate placement of EKG electrodes
EP3763711A1 (en) * 2019-07-09 2021-01-13 Allinky Biopharma Tetrahydroisoquinoline compounds

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577215B2 (ja) * 1987-01-16 1997-01-29 化研生薬株式会社 ベンジルイソキノリン誘導体
AR119149A1 (es) * 2019-06-12 2021-11-24 Arkuda Therapeutics Derivados de isoquinolina como moduladores de la progranulina

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3483206A (en) * 1967-12-15 1969-12-09 Ciba Geigy Corp N-isoquinolylalkanoyl-n-arylamines
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
US3634429A (en) * 1969-09-30 1972-01-11 Hoffmann La Roche Morphinan derivatives and preparation thereof
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
US3483206A (en) * 1967-12-15 1969-12-09 Ciba Geigy Corp N-isoquinolylalkanoyl-n-arylamines
US3634429A (en) * 1969-09-30 1972-01-11 Hoffmann La Roche Morphinan derivatives and preparation thereof
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767862A (en) * 1985-07-23 1988-08-30 Smithkline Beckman Corporation Substituted tetrahydro isoquinoline intermediates
US4678853A (en) * 1986-01-15 1987-07-07 T P O "Pharmachim" 1-(3,4-dimethylbenzyl)-2-(N-alkyl)-carbamoyl tetrahydroiso quinolines
RU2141478C1 (ru) * 1995-06-07 1999-11-20 Пфайзер Инк. Амиды, фармацевтическая композиция, способы снижения секреции аполипопротеина в, соединение
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6172084B1 (en) 1997-06-19 2001-01-09 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO1998057952A1 (en) * 1997-06-19 1998-12-23 Sepracor Inc. Isoquinoline-indole compounds as antimicrobial agents
US6376670B1 (en) 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US20040149658A1 (en) * 2001-08-03 2004-08-05 Dukhin Andrei S. Method for the removal of heavy metals from aqueous solution by means of silica as an adsorbent in counter-flow selective dialysis
US20060229524A1 (en) * 2005-04-08 2006-10-12 Alden Ozment Method for the accurate placement of EKG electrodes
WO2006110542A3 (en) * 2005-04-08 2007-07-26 Alden Ozment Method for the accurate placement of ekg electrodes
EP3763711A1 (en) * 2019-07-09 2021-01-13 Allinky Biopharma Tetrahydroisoquinoline compounds
WO2021005165A1 (en) * 2019-07-09 2021-01-14 Allinky Biopharma Tetrahydroisoquinoline compounds

Also Published As

Publication number Publication date
JPS5041873A (no) 1975-04-16
AR205380A1 (es) 1976-04-30
CA1041501A (en) 1978-10-31
BE817917A (fr) 1975-01-22
IE39630L (en) 1975-01-23
DK138644C (no) 1979-03-19
SE387341B (sv) 1976-09-06
ES448973A1 (es) 1977-11-16
DE2435168A1 (de) 1975-02-06
CH605774A5 (no) 1978-10-13
FR2238488A1 (no) 1975-02-21
AR202416A1 (es) 1975-06-06
GB1452398A (en) 1976-10-13
DK395174A (no) 1975-03-10
ZA744665B (en) 1975-09-24
FR2238488B1 (no) 1978-06-30
NL7409881A (nl) 1975-01-27
AT329563B (de) 1976-05-25
ATA602874A (de) 1975-08-15
NO742679L (no) 1975-01-24
NO141160B (no) 1979-10-15
CH605773A5 (no) 1978-10-13
ES428503A1 (es) 1976-12-16
IE39630B1 (en) 1978-11-22
AU7147074A (en) 1976-01-22
DK138644B (da) 1978-10-09
SE7409496L (no) 1975-01-24
NO141160C (no) 1980-01-23

Similar Documents

Publication Publication Date Title
US3905982A (en) 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds
US3813404A (en) Tropane-2-carboxylates and derivatives
CA1051886A (en) 1,3-dihydrospiro (isobenzofuran) s and derivatives thereof
US4358455A (en) Aralkylamindethanol heterocyclic compounds
JPS59110691A (ja) １−フエニルイソキノリン誘導体
US4539413A (en) Preparation of 3-amino-1-[(1,4-benzodioxan)-2-yl-methoxy]-2-propanols
US3674799A (en) (4'-(phenyl-3 6-dihydro-1-(2h)-pyridyl)-2-hydroxy propoxy-anilides and derivatives thereof
US3910915A (en) 1-Aryl-2-{8 (substituted amino)alkanoyl{9 -1,2,3,4-tetrahydroisoquinolines
US4166117A (en) 1-(Aralkyl)-4-(4-oxo[3H]quinazolin-3-yl)piperidines
US4220778A (en) 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof
JPS6187665A (ja) ジーまたはテトラヒドロイソキノリン誘導体、それらの製造法、およびそれらを含有する医薬組成物
US4069221A (en) 1-(1-Naphthoxy)-3-(4-substituted-piperidino)-2-propanols
US3238212A (en) 1-substituted-1-phenyl(or substituted phenyl)-2-[2-methyl-6, 7-substituted-1, 2, 3, 4-tetrahydroisoquinolinyl-(1)] ethanes
US3211792A (en) 1-(phenyl)-or 1-(alkyl-substitutedphenyl)-5-(substituted-phenyl)-3-aza penta-(1)-ols and salts thereof
US4058531A (en) Process for the preparation of 14-hydroxymorphinan derivatives
WO1990001025A1 (en) Enamine quaternary compounds, methods of making and their use as muscle relaxants
US4772705A (en) Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines
US3452010A (en) 1,3,4,6,7,11b-hexahydro-1,4-oxazino (3,4-a)-isoquinolines
US3557122A (en) 5,6,7a,8,11,11a,12,12a-octahydroindolo (2,1-a)isoquinolin-9(10h)-ones
US4118494A (en) Substituted 3,4-dihydro-2H-isoquinolin-1-thiones
US4312876A (en) Antidepressive and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
US3324139A (en) 3-(3-hydroxyphenyl)-1-phenacylpiperidine compounds
JPS62258371A (ja) ベンゾチアジノン誘導体およびその製造法
US4105849A (en) [(Substituted )phenyl]phenylmethyl-1-(dialkylaminoalkyl)piperidines
US2951013A (en) Antispasmodic compounds and compositions comprising basically substituted derivatives of 1-benzyl tetrahydroiso-quinoline